Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines.

These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’.

At Roche, ‘Personalised Healthcare’ is at the core of our business strategy.

Our expanding knowledge and understanding of disease mechanisms combined with our molecular biology and technology expertise, are leading us to more targeted therapies, and clinically differentiated products.

Already, we have applied world-class, top level science across the entire value chain to benefit the patient. Treatments for breast and gastric cancer, hepatitis B and hepatitis C are early successes.

Kiyotaka Hirose

Take for example, Kiyotaka Hirose who, as part of the Personalised Healthcare approach, was receiving a targeted treatment to fight his infection with the hepatitis C virus.

Hirose: Life was wonderful; I truly enjoyed playing the piano. But then I received the diagnosis that I was infected with the hepatitis C virus. First I lost all hope. But in discussions with my doctor I gained new optimism. Based on my test results he recommended treatment for seven months.

Speaker: Tests offered by Roche Diagnostics provide detailed information on the quantity and sub-type of the hepatitis C virus. With this information the physician could personalise the treatment of Kiyotaka Hirose for 28 weeks instead of standard therapy for 48 weeks.

Hirose: I regained strength and fully enjoy piano playing and life.

Value of Personalised Healthcare

Clearly, the value of the ‘Personalised Healthcare’ approach is rooted in positive outcomes for the patient – saving lives and improving the quality of life.

But other stakeholders benefit as well.

  • Physicians realise easier decision-making, and better prediction of treatment outcome.Payers and reimbursers see the optimised use of resources and the potential reduction of co-treatments for side effects.
  • And regulators and policymakers find a stronger basis for the development of treatment guidelines.

Simply stated, there is no company in the world in a better position to make this approach a reality.

More stories